Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
July 14, 2022 09:00 ET | Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
LMAO logo.jpg
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
June 07, 2022 08:30 ET | LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
April 14, 2022 08:37 ET | Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
March 15, 2022 08:04 ET | ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
February 08, 2022 06:39 ET | Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
November 29, 2021 08:05 ET | ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 08:19 ET | Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment
July 27, 2021 09:00 ET | Informa Business Intelligence
NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, released its first “Patient Perspectives on Clinical...
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
October 21, 2019 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
ProQR logo1200x1200.png
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
October 10, 2019 06:00 ET | ProQR Therapeutics N.V.
Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...